Cambridge Trust Co. reduced its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 34.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 729 shares of the medical instruments supplier’s stock after selling 390 shares during the period. Cambridge Trust Co.’s holdings in C.R. Bard were worth $230,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of BCR. Parallel Advisors LLC boosted its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after buying an additional 369 shares during the last quarter. Cribstone Capital Management LLC bought a new stake in C.R. Bard during the first quarter valued at $130,000. Contravisory Investment Management Inc. boosted its stake in C.R. Bard by 349.2% in the first quarter. Contravisory Investment Management Inc. now owns 548 shares of the medical instruments supplier’s stock valued at $136,000 after buying an additional 426 shares during the last quarter. Whittier Trust Co. boosted its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 42 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new stake in C.R. Bard during the first quarter valued at $148,000. Hedge funds and other institutional investors own 85.32% of the company’s stock.

C.R. Bard, Inc. (NYSE BCR) opened at 318.94 on Tuesday. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $323.27. The stock has a 50 day moving average of $317.93 and a 200 day moving average of $279.50. The company has a market cap of $23.18 billion, a price-to-earnings ratio of 41.87 and a beta of 0.59.

C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the prior year, the firm posted $2.54 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. Equities research analysts predict that C.R. Bard, Inc. will post $11.79 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio is currently 13.67%.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/08/08/cambridge-trust-co-decreases-position-in-c-r-bard-inc-bcr.html.

Several research firms have weighed in on BCR. BidaskClub cut shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Zacks Investment Research cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Raymond James Financial, Inc. restated a “market perform” rating and issued a $265.00 price objective on shares of C.R. Bard in a research report on Tuesday, April 25th. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. C.R. Bard presently has a consensus rating of “Hold” and a consensus target price of $285.67.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.